Serum insulin-like factor 3 quantification by LC–MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome
- 22 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 71 (3), 578-585
- https://doi.org/10.1007/s12020-021-02609-0
Abstract
Purpose Insulin-like factor 3 (INSL3) is an emerging testicular marker, yet larger studies elucidating the clinical role of INSL3 in patients with hypogonadism are lacking. The aim was to describe serum INSL3 concentrations analyzed by LC–MS/MS methodology in males with hypogonadotropic hypogonadism (HH) and Klinefelter syndrome (KS). Methods This was a combined study from two tertiary centers in Denmark and France analyzing INSL3 concentrations by LC–MS/MS. In total, 103 patients with HH and 82 patients with KS were grouped into treated (HH: n = 96; KS: n = 71) or untreated (HH: n = 7; KS: n = 11). Treatment modalities included testosterone and hCG. Serum concentrations and standard deviation (SD) scores of INSL3, total testosterone, and LH according to age and treatment were evaluated. Results In both HH and KS, INSL3 concentrations were low. In HH, INSL3 was low regardless of treatment, except for some hCG-treated patients with normal concentrations. In untreated HH, testosterone was low, while normal to high in most testosterone- and hCG-treated patients. In untreated KS, INSL3 and testosterone concentrations were low to normal, while in testosterone-treated KS, serum INSL3 was low in most patients. INSL3 SD scores were significantly lower in untreated HH than in untreated KS (p = 0.01). Conclusions The dichotomy between lower INSL3 and higher testosterone concentrations, particularly observed in hCG-treated patients with HH, confirms that INSL3 is a different marker of Leydig cell function than testosterone. However, the clinical application of INSL3 in males with hypogonadism remains unclear.Funding Information
- The Absalon Foundation
This publication has 32 references indexed in Scilit:
- Insulin-like Factor 3 Emerges from the Shadow of Testosterone as a Leydig Cell BiomarkerJournal of Clinical Endocrinology & Metabolism, 2020
- Longitudinal Increases in Serum Insulin-like Factor 3 and Testosterone Determined by LC-MS/MS in Pubertal Danish BoysJournal of Clinical Endocrinology & Metabolism, 2020
- INSL3 as a Biomarker of Leydig Cell FunctionalityBiology of Reproduction, 2013
- Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trialFertility and Sterility, 2012
- Insulin-Like Factor 3 Levels in Second-Trimester Amniotic FluidJournal of Clinical Endocrinology & Metabolism, 2008
- Insulin-Like Factor 3 Levels in Cord Blood and Serum from Children: Effects of Age, Postnatal Hypothalamic-Pituitary-Gonadal Axis Activation, and CryptorchidismJournal of Clinical Endocrinology & Metabolism, 2007
- The Effects of Gonadotropin Suppression and Selective Replacement on Insulin-Like Factor 3 Secretion in Normal Adult MenJournal of Clinical Endocrinology & Metabolism, 2006
- Insulin-Like Factor 3 Serum Levels in 135 Normal Men and 85 Men with Testicular Disorders: Relationship to the Luteinizing Hormone-Testosterone AxisJournal of Clinical Endocrinology & Metabolism, 2005
- A Novel Circulating Hormone of Testis Origin in HumansJournal of Clinical Endocrinology & Metabolism, 2004
- Paracrine regulation of mammalian oocyte maturation and male germ cell survivalProceedings of the National Academy of Sciences of the United States of America, 2004